Mastocytosis
Return to Library
|
Free Mastocytosis Articles |
|
|
|
|
Researchers from University of Texas report on findings in acute myeloid leukemia
2009 JUN 22 - (NewsRx.com) -- According to recent research published in the journal Cancer Research, "Kit is a membrane-bound tyrosine kinase and receptor for stem cell factor (SCF) with a crucial role in hematopoiesis. Mutations of KIT occur in almost half of patients with core-binding factor leukemias, in which they have been associated with worse outcome." "Development of new compounds targeting Kit may therefore hold promise for therapy. We investigated the activity and mechanism of action of APcK110, a novel Kit inhibitor, in the mastocytosis cell line HMC1.2 (KITV560G and KITD816V), acute myeloid leukemia (AML) tines OCIM2 and OCI/AML3 (both wild-type), and primary samples from patients with AML," wrote S. Faderl and colleagues, University of Texas. The researchers concluded: "We show that (a) APcK110 inhibits proliferation of the mastocytosis cell line HMC1.2." Faderl and colleagues published their study in Cancer Research (Kit Inhibitor APcK110 Induces Apoptosis and Inhibits Proliferation of Acute Myeloid Leukemia Cells. Cancer Research, 2009;69(9):3910-3917). For additional information, contact S. Faderl, University of Texas MD Anderson Cancer Center, Dept. of Leukemia, Unit 428, 1515 Holcombe Blvd., Houston, TX 77030, USA. The publisher's contact information for the journal Cancer Research is: American Association Cancer Research, 615 Chestnut St., 17TH Floor, Philadelphia, PA 19106-4404, USA. Keywords: United States, Houston, Acute Myeloid Leukemia, Apoptosis, Cancer, Cancer Research, Drug Development, Enzyme Research, Hematology, Hematopoiesis, Kinase, Mastocytosis, Oncology, Pharmaceuticals, Proteins, Proteomics, Stem Cell Research, Therapy, Treatment, Tyrosine Kinase, University of Texas. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
